secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIMEDX GROUP, INC. (MDXG)
CIK:        0001376339
Form:       8-K
Filed at:   2026-02-25T23:59:59+00:00
Accession:  0001376339-26-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MiMedx posts record Q4 sales $118M (+27% YoY); 2026 guidance $340-360M; $100M buyback
--------------------------------------------------------------------------------

- Q4 net sales $118M, +27% YoY; full-year $419M, +20% YoY.
- Q4 GAAP net income $15M ($0.10 EPS); Adjusted EBITDA $29M (25% margin).
- 2026 net sales guidance $340-360M, down from 2025 actual; Adj EBITDA margin mid-to-high teens.
- Board authorizes $100M share repurchase program over two years.
- Cash & equivalents $166M; net cash $148M; SG&A up 18% to $266M on higher commissions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1376339/000137633926000012/0001376339-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1376339/000137633926000012/mdxg-20260225.htm
  HTML page:      https://secwatch.observer/filing/0001376339-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer